•
Mar 31, 2021

Humana Q1 2021 Earnings Report

Humana's financial performance was solid in Q1 2021, driven by strong membership growth and improved profitability.

Key Takeaways

Humana reported a strong start to the year with solid results across the company's segments, fueled by Medicare Advantage and state-based membership growth. The company reaffirms its full-year adjusted EPS financial guidance.

Reported Q1 2021 GAAP earnings per diluted common share of $6.39 and adjusted earnings per diluted common share of $7.67.

Reaffirmed the full-year 2021 adjusted EPS guidance of $21.25 to $21.75, while acknowledging continued uncertainty surrounding the pandemic.

Reaffirmed the full-year 2021 expected individual Medicare Advantage membership growth range of approximately 425,000 to 475,000 members.

Saw solid performance across all company segments driven by strong individual Medicare Advantage and state-based membership growth, plus improved profitability in the Group and Specialty and Healthcare Services segments.

Total Revenue
$20.8B
Previous year: $18.9B
+9.6%
EPS
$7.67
Previous year: $5.4
+42.0%
Gross Profit
$18.7B
Previous year: $16.8B
+11.0%
Cash and Equivalents
$547M
Previous year: $2.35B
-76.8%
Free Cash Flow
-$1.13B
Previous year: $282M
-499.6%
Total Assets
$37.4B
Previous year: $34.6B
+8.0%

Humana

Humana

Humana Revenue by Segment

Forward Guidance

Humana is revising its GAAP EPS guidance range for the year ending December 31, 2021 (FY 2021) to $19.62 to $20.12 from the previous range of $20.82 to $21.32, reflecting the 1Q21 impact of the company's non-consolidating minority interest put/call valuation adjustments and the change in the fair market value of publicly-traded equity securities held by the company. While continuing to acknowledge the heightened uncertainty surrounding the ongoing pandemic, Humana is maintaining its FY 2021 Adjusted EPS guidance range of $21.25 to $21.75.